ES398678A1 - Fused ring indole derivatives - Google Patents

Fused ring indole derivatives

Info

Publication number
ES398678A1
ES398678A1 ES398678A ES398678A ES398678A1 ES 398678 A1 ES398678 A1 ES 398678A1 ES 398678 A ES398678 A ES 398678A ES 398678 A ES398678 A ES 398678A ES 398678 A1 ES398678 A1 ES 398678A1
Authority
ES
Spain
Prior art keywords
group
lower alkyl
compound
aryl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES398678A
Other languages
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
John Wyeth and Brother Ltd
Original Assignee
John Wyeth and Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Wyeth and Brother Ltd filed Critical John Wyeth and Brother Ltd
Publication of ES398678A1 publication Critical patent/ES398678A1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/38Oxygen atoms in positions 2 and 3, e.g. isatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

A procedure for preparing an indole derivative of the general formula (I) **(See formula)** in which R represents a hydroxyl, lower alkoxy, aryl-lower alkoxy, tetrahydropyranyloxy or acyloxy group, and R1 represents a monocyclic or bicyclic aryl radical or a group of aryl-lower alkyl, lower alkyl, lower alkenyl, lower alkynyl or amino-lower alkyl, O well R and R1 taken together represent an oxo, alkylencetal or di- (lower alkoxy) group; R2 and R5, which may be the same or different, represent hydrogen, hydroxy, lower alkyl, lower alkoxy, haloalkyl lower, halogen, amino or mono- or di (lower) alkyl-amino or, if R and R1 together represent a group of oxo, alkylencetal or di- (lower alkoxy), R2 and/or R5 may also represent nitro. R3 and R4 which may be the same or different, represent hydrogen or lower alkyl radicals, or R3 represents hydrogen and R4 represents hydroxyl; n represents 0, 1 or 2; the dashed line represents an optional link at the indicated position; and R6 which is present only when the optional bond represented by the broken line does not exist, represents hydrogen or a radical of aryl-lower alkyl, lower alkyl, lower alkenyl, lower alkynyl, amino-lower alkyl or acyl, or a quaternary ammonium or acid addition salt of said derivative, characterized in that, in a first phase, if desired, a subgeneric compound of the general formula (I) is hydrolyzed, in which R2, R3, R4, R5 and n they have the same meaning as before, while R and R1 together represent an alkylene cetal or di- (lower alkoxy) radical, or optionally, in this previous phase, a ketone of the general formula (III) is cyclized **(See formula)** in which R2, R3, R4, R5 and n have the same meaning as before and X is halogen, and, if desired, conversion of one group R2 and/or R5 into another group R2 and/or R5 by known methods; and, the product resulting from said optional preliminary phase, consisting of a ketone of the general formula (II) **(See formula)** in which R2, R3, R4, R5 and n have the same meaning as before, except that neither R2 nor R5 represent nitro, it is reacted with an organometallic compound, preferably a Grignard reagent type R1MgY, where Y is a halogen, an aryl lithium or sodium or potassium acetylide, and is as defined above and in a special case R1 represents a phenyl radical, halophenyl or alkylphenyl and more especially R2, R3, R4 and R5 each represent hydrogen atoms, the reagent of which allows the conversion of a ketone function into the group (see graph) and, if desired, alkylating or acylating the resulting compound, of formula (I), in which R represents a hydroxyl group and the dashed line represents a bond, to form a respective compound in which R represents a lower alkoxy, aryl-lower alkoxy, tetrahydropyranyloxy or acyloxy radical; in turn, if desired, converting the compound of the general formula (I) in which the dashed line represents a bond into a respective quaternary ammonium or acid addition salt; reduce, if desired, the compound in which the dashed line represents a bond, or its quaternary ammonium salt, to obtain a compound of formula (I) in which the bond represented by the dashed line does not exist and R6 represents an aryl-lower alkyl, lower alkyl, lower alkenyl, lower alkynyl or amino-lower alkyl group; converting the resulting compound, if desired, to a respective quaternary ammonium or addition salt; and, if desired, in any product convert a group R and/or R1 and/or R2 and/or R3 and/or R4 and/or R5 and/or R6 (if any) into another group R and/or R1 and/or R2 and/or R3 and/or R4 and/or R5 and/or R6 within the meanings defined above when dealing with formula (I) above. (Machine-translation by Google Translate, not legally binding)
ES398678A 1971-01-11 1972-01-08 Fused ring indole derivatives Expired ES398678A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB125071*[A GB1366133A (en) 1971-01-11 1971-01-11 Fused ring indole derivatives
GB4095971 1971-09-02
GB5646771 1971-12-06

Publications (1)

Publication Number Publication Date
ES398678A1 true ES398678A1 (en) 1975-05-16

Family

ID=27253859

Family Applications (2)

Application Number Title Priority Date Filing Date
ES398678A Expired ES398678A1 (en) 1971-01-11 1972-01-08 Fused ring indole derivatives
ES409296A Expired ES409296A1 (en) 1971-01-11 1972-12-05 Fused ring indole derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES409296A Expired ES409296A1 (en) 1971-01-11 1972-12-05 Fused ring indole derivatives

Country Status (20)

Country Link
JP (1) JPS5531156B2 (en)
AR (1) AR192734A1 (en)
AT (1) AT312595B (en)
AU (1) AU464388B2 (en)
BE (1) BE777911A (en)
CA (1) CA1012150A (en)
CH (1) CH573938A5 (en)
CY (1) CY926A (en)
DK (1) DK150143C (en)
EG (1) EG10888A (en)
ES (2) ES398678A1 (en)
FI (1) FI54120C (en)
FR (1) FR2121699B1 (en)
GB (1) GB1366133A (en)
HK (1) HK52877A (en)
IE (1) IE35956B1 (en)
KE (1) KE2777A (en)
MY (1) MY7800048A (en)
NL (1) NL174251C (en)
SE (1) SE398645B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1520611A (en) * 1976-06-11 1978-08-09 Wyeth John & Brother Ltd Fused ring indole derivatives
JPS5845741B2 (en) * 1977-06-06 1983-10-12 株式会社日立製作所 information retrieval device
ZA824382B (en) * 1981-07-07 1984-02-29 Wyeth John & Brother Ltd Anti-obesity agents
JPS60204057A (en) * 1984-03-28 1985-10-15 Casio Comput Co Ltd Small-sized electronic apparatus with data storage function
GB8606254D0 (en) * 1986-03-13 1986-04-16 Wyeth John & Brother Ltd Substituted pyrimidoindoles
GB8606253D0 (en) * 1986-03-13 1986-04-16 Wyeth John & Brother Ltd Pyrimidoindoles
GB8614246D0 (en) * 1986-06-11 1986-07-16 Wyeth John & Brother Ltd Substituted pyrimidoindoles
WO2010090680A1 (en) * 2008-12-15 2010-08-12 Wyeth Llc Substituted oxindole cb2 agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888846A (en) * 1967-03-30 1975-06-10 Hoffmann La Roche Process for 2(2-(1,3-diazacycloalk-2-enyl))benzophenone derivatives and 1,3-diazacycloalkenyl(2,1-a)isoindole derivatives
US3586693A (en) * 1969-07-07 1971-06-22 American Home Prod Imidazo(1,2-a)indolin-9-ols

Also Published As

Publication number Publication date
SE398645B (en) 1978-01-09
FI54120B (en) 1978-06-30
AU3755872A (en) 1973-07-05
JPS4839500A (en) 1973-06-09
GB1366133A (en) 1974-09-11
CH573938A5 (en) 1976-03-31
HK52877A (en) 1977-10-20
FR2121699B1 (en) 1975-08-01
FI54120C (en) 1978-10-10
AR192734A1 (en) 1973-03-14
MY7800048A (en) 1978-12-31
DK150143C (en) 1987-06-01
EG10888A (en) 1978-06-30
ES409296A1 (en) 1976-03-16
IE35956B1 (en) 1976-07-07
KE2777A (en) 1977-10-21
CA1012150A (en) 1977-06-14
CY926A (en) 1977-12-23
NL7200415A (en) 1972-07-13
NL174251C (en) 1984-05-16
IE35956L (en) 1972-07-11
FR2121699A1 (en) 1972-08-25
NL174251B (en) 1983-12-16
BE777911A (en) 1972-07-11
AU464388B2 (en) 1975-08-28
JPS5531156B2 (en) 1980-08-15
AT312595B (en) 1974-01-10
DK150143B (en) 1986-12-15

Similar Documents

Publication Publication Date Title
GB1293303A (en) Thiohydantoin derivatives, processes for producing them and compositions containing them
ES398678A1 (en) Fused ring indole derivatives
ES396134A1 (en) 1,1,1-trichloro-2-amido-2-amino-ethanes
NL7510047A (en) PROCESS FOR THE PREPARATION OF PHENYL METHYLCARBINOL.
ES389497A1 (en) Fastener retainer
ES412966A1 (en) 21-orthoesters of cortical steroids and methods of preparing same
GB1128052A (en) Alkanolamine derivatives
ES392848A1 (en) Indenopyrrole derivatives
ES421182A1 (en) Propanolamine derivatives
NL7410826A (en) PROCESS FOR THE PREPARATION OF INDAZOLE-3-CARBONIC ACID HYDRAZIDES.
ES308388A2 (en) A procedure for preparing an insecticide composition. (Machine-translation by Google Translate, not legally binding)
GB1210826A (en) Substituted-phenyl thiophosphorus acid esters and pesticidal compositions containing them
GB669179A (en) Organo silicon compounds
GB970954A (en) Preparation of phenazasilines and intermediates in that preparation
GB1085997A (en) Manufacturing method of imidazolidinone derivatives
GB855202A (en) Method for preparation of polystyrene
ES321534A1 (en) Procedure for the preparation of compounds of dihidrodibenzociclohepteno. (Machine-translation by Google Translate, not legally binding)
ES354265A1 (en) Procedure for preparing bis-N-phosphorillate compounds. (Machine-translation by Google Translate, not legally binding)
GB1071124A (en) Derivatives of pyrazolo-[4',5'-b]-11-oxo-18ª‡- and 18ª‰-olean-12-en-30-oic acid
GB1311773A (en) Phosphorothiolates and processes for preparing them
GB996241A (en) A process for preparing 1,2-disubstituted-3,5-dioxo-4-(gamma-oxobutyl)-pyrazolidines
GB1131598A (en) Inosine acetals
GB1142227A (en) Urethane derivatives of dihydropyran and polymerisation thereof
ES377139A1 (en) A method of preparing a salt of pirrilvinyltyazolio. (Machine-translation by Google Translate, not legally binding)
GB1120047A (en) Cyanine dyes